POPULARITY
10 episodes with compounded
14 episodes with compounded
9 episodes with compounded
10 episodes with compounded
26 episodes with compounded
6 episodes with compounded
8 episodes with compounded
5 episodes with compounded
8 episodes with compounded
3 episodes with compounded
8 episodes with compounded
3 episodes with compounded
6 episodes with compounded
4 episodes with compounded
4 episodes with compounded
3 episodes with compounded
7 episodes with compounded
2 episodes with compounded
Comedians Sal Vulcano & Shane Gillis join Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir to celebrate Ari's time as a cohost of Legion of Skanks and offer their heartfelt goodbyes before his big move to London, England. Plus, the guys have some fun with Sal's pepper spray and the prospective interns, and the gang reviews the long awaited bodycam footage from Luis' 911 call from the car dealership where a worker threatened him with a sword. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 06/16/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodSupport the show & get 20% off your Ruiget order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com.Don't sleep on @ultrapouches. New customers get 15% off with code LEGION at http://takeultra.com #UltraPouchesOne thing to pack, five ways to power! Get up to 40% off @ Ridge during their Father's Day Sale at https://www.Ridge.com/LOS10 #RidgepodSave 10% off + an extra $10 discount on your Starter Kit purchase today by using code LEGION at https://www.bruntworkwear.com/LEGION #Bruntpod---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Comedians H. Foley & Kevin Ryan join Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir for the third round of the 2026 Springtern Olympics! The guys discuss the influencer couple who recently announced the terminate their pregnancy after a down syndrome diagnosis. Plus, Foley and Kev analyze the interns and place them on a sliding scale of garbage, then the bottom two battle for their spot in a syrup chugging race. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 06/09/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodSupport the show & get 30% off SITEWIDE for Father's Day at https://www.sheathunderwear.com #SheathPodSupport the show & get 20% off your Ruiget order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com.New customers get 40% off with code SKANKS at http://GLD.com #GLDpodDon't sleep on @ultrapouches. New customers get 15% off with code LEGION at http://takeultra.com #UltraPouches---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
One habit. Practiced daily. Compounded over years. That is the actual price of becoming an excellent leader, and most ambitious people are paying a completely different price instead. Ryan Hawk has spent 11 years hosting The Learning Leader Show, with over 700 conversations with some of the highest-performing people in business, sports, and beyond. His new book, The Price of Becoming, is built on a simple but uncomfortable idea: the thing that separates sustaining excellence from fleeting success is not talent, vision, or even hard work. It's reliability. Consistency. The willingness to go to bed a little wiser than when you woke up, day after day, without interrupting the compounding. I got to sit down with Ryan on the Systematic Leader podcast, and I walked away with a pile of notes and one image I can't stop thinking about. Ryan flew to Boulder, Colorado, to record an interview with Jim Collins, author of Good to Great and one of the most respected names in business. Before they started recording, Collins walked in and began quietly emptying his pockets. Apple Watch. Key fob. Phone. A Ziploc bag with cash and an emergency contact. He placed it all in a neat pile outside the door. Then he walked in. He never mentioned it. Never made a speech about presence. He just removed every possible distraction before the conversation began. Ryan said he asked Collins' assistant about it afterward. Her answer: "Jim is so good about being locked in on what he chooses to do." That story tells you everything about what this episode is about. What Ambitious Leaders Consistently Get Wrong Ryan has asked hundreds of high performers what separates the great ones from everyone else. The answer is almost never what people expect. Not charisma. Not risk tolerance. Not some secret morning routine that takes four hours. The Inner Scoreboard vs. The Outer Scoreboard One of the most useful distinctions in this conversation is the difference between winning externally and winning internally. Ryan has worked with Brooke Cupps, the winningest high school basketball coach at Centerville High School, who has never set a single goal around winning games. Every goal his teams set is a process goal, tied to their core values: tough, passionate, unified, and thankful. The score, Ryan says, seems to take care of itself when your focus is that clear. The leaders who get out of whack are the ones fixated on what others will think, how something will look, or hitting a specific number. That outward focus crowds out the internal work that actually produces results. See It, Say It: The Simplest Culture-Building Practice Ryan shared the framework he uses with his coaching clients, borrowed from his collaborator Garen Stokes. The idea is this: when you observe something worth saying, you say it immediately. Vivid Clarity Is the Leader's Job One theme Ryan returns to again and again is that if someone on your team doesn't know what excellence looks like in their role, that is the leader's fault. Not the employee's. Yours. About Ryan Hawk Ryan Hawk is the host of The Learning Leader Show, one of the longest-running leadership podcasts with over 700 episodes and millions of listeners worldwide. His new book, The Price of Becoming, releases July 21st. Find everything he does at LearningLeader.com. Listen to the full episode on the Systematic Leader Podcast wherever you get your shows. And if you want one practical systems idea in your inbox every week, join the newsletter at systematicleader.co.
Pam Bondi has made the Epstein problem worse because she turned what should have been a sober, victim-centered document process into a rolling credibility disaster. She helped raise expectations with public talk about Epstein material being ready for release, including the now-infamous “client list” confusion, only for the DOJ to later walk that back and say no such list existed. The first “phase” of files was hyped as transparency but largely consisted of previously known or leaked material, and the rollout became a political spectacle involving binders, influencers, and media theater instead of a disciplined legal accounting. That alone damaged trust, because people who already believed the government was hiding something were handed a perfect example of sloppy messaging, overpromising, and underdelivering.Her handling of herself since then has been just as damaging. When pressed by Congress, Bondi defended the DOJ's overall handling while distancing herself from the details, saying Todd Blanche led the Epstein-file release and that she had delegated the process to him. She admitted redaction mistakes but tried to frame the broader effort as transparent, even as reporting has shown that DOJ errors exposed sensitive victim information and intensified harassment against survivors. That is the core failure: instead of restoring confidence, Bondi's posture has looked like a mix of blame-shifting, legal dodging, and political self-preservation. In a case where the government's credibility was already hanging by a thread, she managed to make the public question not only what was being withheld, but whether the people in charge even understood the gravity of what they were handling.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.
Have you been putting off a needed change because life feels too full or the changes feel too big? What if you could make significant, sustainable progress with micro-efforts? Today we're sharing some thoughts, ideas, examples, and questions for you to consider as you learn, do, and become! For Show Notes, please visit https://LearnDoBecome.com/Episode327 Ready for More with LearnDoBecome? Join us for our Free training, "How to Finally Stop Drowning in Piles": https://learndobecome.com/aff/?p=Ldbyt&w=organize Get Your Free LearnDoBecome Welcome Kit Here: https://LearnDoBecome.com/Welcome
Comedian Mark Normand joins Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir for the official opening ceremony of the 2026 Springtern Olympics. The guys interview and nickname all ten intern hopefuls, and three contestants are eliminated in a contest of strength. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 05/26/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodIf you're 21 or older, get 40% OFF your first order @ IndaCloud with code SKANKS at https://inda.shop/SKANKS #indacloudpodSupport the show & get 20% off your Ruiget order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com.For a limited time only, Legion of Skanks fans get 20% off + free shipping by using code SKANKS at checkout at http://blueprint.bryanjohnson.com #BlueprintSave 10% off + an extra $10 discount on your Starter Kit purchase today by using code LEGION at https://www.bruntworkwear.com/LEGION #Bruntpod---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Comedians Steve Rannazzisi & Sienna Hubert Ross join Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir to discuss The Roast of Kevin Hart, Big Jay's beef with D.L. Hughley, FootFinder ratings, and who is going to round two of the Springtern Olympics. Plus, Sienna plays F, marry, kill, befriend with the guys. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 05/19/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodSupport the show & get 20% off your 1st Sheath order with code SKANKS20 at https://www.sheathunderwear.com #SheathPodSupport the show & get 20% off your Ruiget order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com.For a limited time only, Legion of Skanks fans get 20% off + free shipping by using code SKANKS at checkout at http://blueprint.bryanjohnson.com #BlueprintSave 10% off + an extra $10 discount on your Starter Kit purchase today by using code LEGION at https://www.bruntworkwear.com/LEGION #Bruntpod---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Colorectal cancer is now the leading cancer killer in adults under 50, and patients in their 20s are presenting with metastatic disease that has nothing to do with family history. Most physicians are still telling young patients with rectal bleeding that it's probably just hemorrhoids and that's costing lives.In this episode, Dr. Gabrielle Lyon sits down with Dr. Michelle Pearlman, a board-certified gastroenterologist and founder of a Miami-based gastro-metabolic clinic, to discuss:The specific warning signs every adult under 50 should never ignore, regardless of age including rectal bleeding, unintentional weight loss, and persistent abdominal painWhy GLP-1 medications like Ozempic and Zepbound are being miscategorized as weight loss drugs when they're actually metabolic reprogrammers with applications in fatty liver, sleep apnea, and inflammationThe protein, fiber, and resistance training protocol Dr. Pearlman uses to protect muscle mass in patients on GLP-1 therapyHow hormone replacement therapy combined with GLP-1s is changing body composition outcomes for perimenopausal women and why current guidelines are still 20 years behind the dataDr. Pearlman's personal osteoporosis diagnosis at 39, despite being a lifelong bodybuilder, and what it revealed about the diagnostic gaps in standard medicineThis conversation gives you the framework to recognize the warning signs most physicians are still missing, and the foundational habits; nutrition, resistance training, and hormone optimization that protect your gut, bones, and muscle through midlife and beyond.Thank you to our sponsors: Cozy Earth - Go to https://bit.ly/4teXQhz for up to 20% off! Timeline - Get 20% off your Mitopure order at https://bit.ly/4eLBWhB Lucy - Get 20% off your next order with code DRLYON at https://bit.ly/42HiUlc, or find yours in store at https://bit.ly/3RfGnYa Amp - Visit https://bit.ly/3RcmqBz to get your AI-powered at-home gym for smarter, personalized training.Explore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Michelle Pearlman at:Instagram: https://www.instagram.com/michellepearlmanmd/ Website: https://pearlmanmds.com/michelle-pearlman-md/ Connect with Dr. Gabrielle LyonInstagram: https://www.instagram.com/drgabriellelyon/TikTok: https://www.tiktok.com/@drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction: Colorectal cancer under 5001:15 - The gastro-metabolic approach explained03:30 - Why nutrition isn't taught in GI fellowship05:45 - When the colonoscopy is normal but patients suffer07:00 - Weight, reflux, and visceral fat09:15 - PPIs, bone density, and long-term risk11:30 - Three things to never do for gut health14:00 - Ultra-processed food and early-onset cancer16:45 - Rectal bleeding, warning signs, and age19:00 - Screening guidelines and the obesity gap22:30 - GLP-1 medications: history and mechanism27:15 - Hunger, cravings, and food noise30:00 - The stigma around metabolic medications33:45 - Side effects: nausea, reflux, constipation38:30 - Compounded formulations and pharmacy safety42:00 - Hair loss, protein, and supplementation45:15 - Pill versus injection delivery systems49:30 - Fiber, the microbiome, and short-chain fatty acids54:00 - GLP-1s plus hormone replacement therapy58:45 - Testosterone, Kyzatrex, and women's bone health1:03:00 - Pearlman's osteoporosis diagnosis at 391:09:30 - The diagnostic gap in standard medicine1:14:00 - Building Bite MD and the future of nutrition tech Disclaimers: This episode includes paid sponsorships. The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.
Comedians Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir discuss their predictions for the Roast of Kevin Hart, the motivational post that has Luis thinking differently, Khamzat vs Strickland, Michael Jackson's alleged innocence, and Jelly Roll's special moment with a special fan. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 05/12/25Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodOne thing to pack, five ways to power! Get up to 40% off @ Ridge during their Father's Day Sale at https://www.Ridge.com/LOS10 #RidgepodNew customers get 40% off with code SKANKS at http://GLD.com #GLDpodIf you're 21 or older, get 40% OFF your first order @ IndaCloud with code SKANKS at https://inda.shop/SKANKS #indacloudpodSupport the show & get 20% off your Rugiet order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com #RugietPod---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-484 Overview: Muscle growth, tissue repair, sexual function—compounded injectable peptides are marketed online for an expanding list of uses, and they're showing up in your patients' medicine cabinets. Join us as we explore this growing trend, evaluate the evidence behind the claims, and discuss how to counsel patients on potential safety risks. Episode resource links: Expert Opin Drug Saf. 2026 Mar;25(3):581-588. doi: 10.1080/14740338.2025.2499670 HSS J. 2025 Jul 31;21(4):15563316251355551. doi: 10.1177/15563316251355551 JAMA 2017;318;(20):2004-2010. doi:10.1001/jama.2017.17069 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-484 Overview: Muscle growth, tissue repair, sexual function—compounded injectable peptides are marketed online for an expanding list of uses, and they're showing up in your patients' medicine cabinets. Join us as we explore this growing trend, evaluate the evidence behind the claims, and discuss how to counsel patients on potential safety risks. Episode resource links: Expert Opin Drug Saf. 2026 Mar;25(3):581-588. doi: 10.1080/14740338.2025.2499670 HSS J. 2025 Jul 31;21(4):15563316251355551. doi: 10.1177/15563316251355551 JAMA 2017;318;(20):2004-2010. doi:10.1001/jama.2017.17069 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Do not overlook the compounded humanitarian crisis in Lebanon - Bilal Nasser by Radio Islam
“Bioidentical.” “Compounded.” “Customized for you.”These terms are everywhere in menopause care but what do they actually mean?In this episode, we sit down with pharmacist, Dr. Hollie Wakelyn, PharmD, BCACP, MSCP, who shares her deep expertise in hormone therapy to separate fact from fiction. We dive into the real differences between approved hormones and compounded products, why so many women are being steered toward them, and what most people aren't being told about safety, regulation, and outcomes.--
It started with a $61,500 home in Modesto and $11,500 down.
Comedians Tristan Bowling & Lev Fer join Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir to discuss Big Jay's road rage incident, Russell Brand's new persona amidst allegations of sexual misconduct, and who lives in a more suburban neighborhood between Luis and Big Jay. Plus, friends of the show Josie Marcellino and Erin Lipski have major beef. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 04/28/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodSupport the show & get 20% off your Rugiet order with code skanks at https://www.rugiet.com/skanks Rugiet prescriptions are compound medications, available only if prescribed after an online consultation with a licensed clinician. Compounded drugs can be prescribed under federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information is available at https://www.rugiet.com #RugietPodVisit https://prizepicks.onelink.me/LME0/SKANKS & use code SKANKS to get $50 in lineups when you play your first $5 lineup!Don't sleep on @ultrapouches. New customers get 15% off with code LEGION at http://takeultra.com #UltraPouches #adIf you're 21 or older, get 40% OFF your first order @ IndaCloud with code SKANKS at https://inda.shop/SKANKS #indacloudpod---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Business leaders are operating in a harsher, more expensive, and more politically volatile environment, where geopolitics is now showing up directly in fuel costs, inflation, supply chains, capital markets, alliance structures, and executive decision-making. I'm Dominic Bowen, host of The International Risk Podcast, where we unpack the issues shaping business, leadership, and global risk.Today, the operating environment for business is clear. The Iran conflict is pushing up oil and gas prices. The Strait of Hormuz is back at the centre of global trade risk. Eurozone inflation is reacting to energy costs. Questions are being raised about NATO cohesion and US alliance commitments. And the shockwaves are spreading well beyond energy into shipping, semiconductors, sovereign debt, industrial inputs, and broader business confidence.Our guest today is Jon-Paul Gabriele. He is the founder of Crisis City and brings more than 15 years of crisis management experience. Today, we are discussing the gap between having a crisis management plan and actually leading under pressure.The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical volatility and organised crime, to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter.The International Risk Podcast is sponsored by Conducttr, a realistic crisis exercise platform. Conducttr offers crisis exercising software for corporates, consultants, humanitarian, and defence & security clients. Visit Conducttr to learn more.Dominic Bowen is the host of The International Risk Podcast and Europe's leading expert on international risk and crisis management. As Head of Strategic Advisory and Partner at one of Europe's leading risk management consulting firms, Dominic advises CEOs, boards, and senior executives across the continent on how to prepare for uncertainty and act with intent. He has spent decades working in war zones, advising multinational companies, and supporting Europe's business leaders. Tell us what you liked!
Stabilize the Compounded Grief w RESET: Tasha Mac"High performers don't struggle because they lack discipline, skill, or drive. They struggle because disruption destabilizes identity… and no one taught them how to stabilize it.https://www.iamcoachtashamac.com/*PinkCloud9 Media Podcast Show Curator Show Host: Pink the Disruptive Forcehere where HUMANITY × BUSINESS500+ CEO EPISODES100K BIZ AUDIENCE20+ YRS Marketing HARVARD RESEARCHPodcaster · Live Streamer Producing CEO-level interviews since 2020. Executives & Investors are in the room.Just 15 minutes — looking for Authors, Speakers, Coaches, Entrepreneur conversations and you walk away with real, lasting visibility too YOU GET→ Evergreen content→ Full media kit→ Mini PR campaign→ 2027 Marketing→ Audience positioning→ Distribution+https://calendly.com/pinkcloud9podcast/actual-recording-here-be-readyBOOK here #pinkcloud9media #sponsored #donation #podcast #collaboration
ALSO: IMPD help families navigating homicide aftermath, student ID voting ban, Carmel council hears from residents over ICE office, Pakistan to host U.S. & Iran for second peace talks, and Colts GM Chris Ballard ahead of the NFL Draft.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Shop all my verified, tested and preferred wellness products - includes most up to date brands: https://theswellscore.com/pages/drg Episode Description Peptides are everywhere right now. But nobody's telling you the part that actually matters. Your feed is full of peptide content — faster recovery, anti-aging, performance, healing. And some of it is real. But peptides aren't supplements. They are biological signals that tell your cells how to behave. And when you treat them all like one category, you're not just wasting money — you're gambling with your biology. Dr. G breaks down the full peptide landscape so you can stop guessing and start making an actual informed decision. In this episode, you'll learn: • The 3 tiers of peptides — from FDA-approved medicine to experimental compounds with zero human safety data — and exactly where the popular ones fall • Why the same peptide can be life-changing for one person and harmful for another (it's not placebo — it's physiology) • How to evaluate sourcing, purity, and contamination risk before injecting anything into your body Timestamps: 0:00 - Intro 1:13 - Why Peptides Exploded Into Mainstream Wellness Culture 3:19 - What Peptides Actually Do Inside the Body 4:57 - The Cancer Question: Why Growth Signaling Demands Respect 6:22 - The Three Tiers of Peptides (And Which Has Real Human Data) 9:46 - Why the Same Peptide Works for One Person and Not Another 10:10 - The Four Variables That Determine Your Response 13:06 - How to Evaluate a Peptide Before You Put It in Your Body 14:00 - FDA Approved vs. Compounded vs. Research Use Only: What's the Difference 15:50 - Contamination Risk and What's Actually in That Vial 16:31 - The Minimum Safety Framework If You Choose to Use Peptides 17:41 - Final Word: Optimize Your Foundation Before Adding Peptide Learn more about your ad choices. Visit megaphone.fm/adchoices
What if the blueprint for thriving in the AI era has been buried for centuries, inside the civilization that built the pyramids? Organizational psychologist Christine Mikhail joins Lori Adams-Brown live from the Transform Conference in Las Vegas to unpack one of the most urgent (and under-discussed) challenges in the modern workplace: we're racing to implement AI, but we're forgetting the humans doing the work. In this episode, you'll discover: Why Christine coined "compounded change" and why your workforce is carrying more layers of transformation than anyone is acknowledging The ancient Egyptian precedent: when women held positions of finance, governance, and pharaonic leadership and what modern society lost when that changed The critical AI adoption gap: organizations are deploying new technology without addressing the psychological and emotional responses of their people How change resilience workshops create unexpected catharsis and build communities people didn't know they needed How to frame AI as a tool that elevates human capability, and why that framing is the difference between adoption success and workforce anxiety Christine Mikhail is a master's-level industrial-organizational psychologist and founder of Mikhail Consulting Group, a consultancy specializing in work design and change management. With roots tracing to ancient Egypt, she brings a uniquely global lens to how humans navigate transformation at work. TIMESTAMPS 00:00 – Welcome from the Transform Conference, Las Vegas 02:17 – Egypt, cultural identity, and a heartbreaking lesson in gender inequality 05:00 – Ancient Egypt's golden era: when women were pharaohs, financiers, and leaders 08:59 – What excites Christine about the future of work and the human-AI relationship 10:59 – The overlooked gap in AI adoption: where is the human change strategy? 13:24 – Upskilling in the AI era: we promise humans will be needed — but for what? 15:49 – "Compounded change" — why this moment feels like a tsunami, earthquake, and ripple at once 18:09 – How change resilience workshops are building community and catharsis 20:27 – AI adoption success: framing technology as "for" people, not a replacement 22:40 – Where to find Christine and Mikhail Consulting Group Find Christine Mikhail at: https://www.linkedin.com/in/christine-mikhail-odconsultant | Mikhail Consulting Group on LinkedIn Subscribe, leave a review at https://www.aworldofdifferencepodcast.com/reviews/new/, and share this episode with five people who need to hear it. Visit https://www.aworldofdifferencepodcast.com for more resources on intercultural leadership and global impact. Learn more about your ad choices. Visit megaphone.fm/adchoices
The data is in. Farms that perform better... perform a lot better. And the gap isn't luck. In this live webinar event from Growing the Future Productions, host Dan Aberhart sits down with three of the sharpest minds working on Saskatchewan farms right now — Darren Sander of Crop-Aid Nutrition, Dave Norris of Norris Crop Consulting, and Todd Rowan of IXL Innovations — for a frank, no-sugarcoating conversation about what separates the producers clearing big margins from the ones leaving money on the table. The number? Somewhere between $50 and $100 per acre. Every single year. Compounded over a decade — it's not a number. It's a different life. What gets covered in this episode: Soil Health & the First 30 Days — Darren makes the case that the first 30 days of a crop dictates maximum yield potential. Not the last 30. The first. That reframe alone is worth your time. He also talks about how a soil health program let his operation move from a three-crop rotation to two — and pencil out better. Earthworms optional, but encouraged. (00:04:00) — Darren breaks down the incremental gains philosophy: fertilizer protection, stress reduction, nutrient use efficiency, and how every acre should be growing the crop it's best suited to grow. Grain Marketing & the Probability Game — Dave Norris and Todd Rowan don't predict the future. They work with probabilities. And when warships started heading toward the Strait of Hormuz, they texted their clients to fill their fuel tanks. Fuel was $1.02. The downside risk was 93 cents. The upside was $1.50. That's not a prediction. That's a risk-reward conversation — and the producers who had that conversation in advance came out a lot better than the ones who watched the news. (00:09:00) — The panel unpacks why so many producers make decisions after it feels urgent, and why the best time to act is almost always when it doesn't. Crop Insurance, In-Season Pricing & the 2025-26 Landscape — It's the worst crop insurance environment since before 2021. The panel digs into what that means for in-season pricing on canola, wheat, and durum, and how to think about layering agri-stability on top when the base numbers aren't what they used to be. (00:22:00) — Dave and Todd walk through the mechanics of in-season pricing, the cash flow timing issue with SCIC payments, and how to think about selling new crop canola when fertilizer costs are still wildly elevated. The Fertilizer Problem Nobody's Talking About Enough — An estimated 400,000-tonne shortage of urea in Saskatchewan this year. Producers who didn't pre-buy are scrambling. The panel discusses how this reshapes planting decisions, top-dressing options, foliar programs as a partial substitute, and why the supply-demand models for yield estimates may be fundamentally broken this season. (00:33:00) — Todd flags what this means for crop rotation flexibility. When the only crop penciling out is canola, what happens to everything else? Macroeconomics, Gold, Oil & the Commodity Supercycle — Dave Norris had a supercycle bias since November. He didn't have a war in March as the trigger — he thought it would be El Niño. He wasn't entirely wrong. The panel talks about money flowing into commodities, what governments printing money means for grain prices, and why canola at $700 a tonne may not be the ceiling. (00:40:00) — The canary in the coal mine: when gold and silver started ripping, the smart money was already watching inflation and currency hedges. Farmers paying attention to macros have a structural edge over those only watching local basis. The $70 Poll — What the Audience Said — Dan ran a live poll with over 150 producers on the call. The majority landed between $50 and $100 per acre as the value of strong management decisions. Todd shared a real-world example: in 2021-22, clients who didn't over-contract and took in-season crop insurance pricing pocketed $18/bushel versus $12. Clients who panicked after 2021 and froze in 2022 took $17 off the combine when $22 was on the board. The math on those decisions — compounded over 10 years — is a different farm. (00:56:00) — The close. Dan pulls together the final takeaways from the audience word cloud, and the panel leaves producers with the most important thing of all: knowing when to act, and not waiting until it's obvious. Featured in this episode: Dan Aberhart — Host, Growing the Future Productions Darren Sander — Crop-Aid Nutrition Dave Norris — Norris Crop Consulting Todd Rowan — IXL Innovations More from Growing the Future: Podcast: growingthefuturepodcast.ca YouTube: Growing the Future Productions Ground Truth Daily: Available wherever you listen to podcasts Register for the Convergence Conference at convergence.ag and stay updated by subscribing to the Growing the Future Podcast at growingthefuturepodcast.ca.
What did it take to achieve the impossible? What was the moment that changed everything? And what advice does Brittany have for those facing their own surgical regrets?The road to restoration is never easy—but for Brittany, it was nearly impossible. In this gripping part 2, Dr. Rady Rahban unravels the next chapter of Brittany's harrowing plastic surgery nightmare, one that left her with devastating complications, shattered confidence, and a seemingly insurmountable battle ahead. After a botched Smart Lipo procedure left her with fibrosis, scarring, and a mutilated abdomen, Brittany spent years searching for answers—only to be told by multiple surgeons that her case was hopeless. But hope found her in the form of Dr. Rahban, who embarked on an ambitious, high-risk journey to rebuild what had been lost. From grueling rounds of fat transfers to a final, transformative tummy tuck, Brittany's story is one of perseverance, trust, and surgical precision. Now, after years of emotional and physical suffering, she finally has the confidence to live without limits. This is an episode you won't want to miss! Listen now to hear the raw, emotional conclusion to Brittney's story. Follow & share to help others avoid life-altering mistakes in plastic surgery.✨ If you enjoyed this episode of Plastic Surgery Uncensored:✔️ Subscribe on Apple Podcasts, Spotify, or wherever you listen.✔️ Rate & Review—your feedback helps more people find us.✔️ Follow Dr. Rady Rahban across all platforms for daily insights, behind-the-scenes, and patient education:Instagram: @drradyrahbanTikTok: @radyrahbanMDYouTube: @Rady RahbanFacebook: @Rady Rahban✔️ Share this episode with someone considering plastic surgery—the right knowledge can save a life.
Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.
Angela tells how as a kid all she wanted was her mom. And all her mom wanted to do was teach her how to melt crack. It's a backstory no one would suspect, including her daughter. DAILY LOOK For 50% off your first order, head to DailyLook.com and use code SECRETROOM. HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET THE NIGHT OWL: TRUE GHOST STORIES Find The Night Owl: True Ghost Stories, ghost stories like you've never heard before, anywhere you get your podcasts. PICTURES See Angela, her parents and grandparents. And of course see her grandma's secret prayer. They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Rose grew up in a country ruled by an authoritarian regime. To escape persecution, she tricked her Dad into helping her flee. How she got out and why she would leave her family are her secret. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries. Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy will lose patent protection in countries such as Brazil, China, and India later this month, and researchers identified 150 countries where it was never patented. These researchers estimated it will cost as little as $3 to produce a month's supply of semaglutide, which in its branded form sells for around $200 a month in the United States. Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate. https://www.sciencealert.com/weight-loss-drugs-could-cost-just-3-a-month-to-make-as-patents-end XX Here in the US the FDA is stepping up its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting telehealth companies it says make "false or misleading" claims about compounded versions of popular obesity drugs. The FDA says Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process." https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters XX Check your infusion sets for an issue: Unomedical, a subsidiary of Convatec and a supplier of insulin infusion sets to diabetes tech firms, has received a warning letter from the FDA. Inspectors raised concerns with leaking infusion sets, following a regulatory assessment of Unomedical's facility in Reynosa, Mexico, last summer. Unomedical supplies infusion sets to insulin pump makers including Medtronic, Tandem Diabetes Care and Beta Bionics. In a Feb. 3 statement, Convatec said the letter focuses on reporting procedures and quality protocols and does not place restrictions on producing, marketing or distributing any of Unomedical's products. Unomedical told the FDA in its responses that it plans to conduct a retrospective review of complaints involving serious injury or death by January and conduct additional training on complaint handling by May. https://www.medtechdive.com/news/fda-warns-insulin-infusion-set-maker-unomedical-over-leaks-mishandled-comp/813503/ XX Nearly four in ten people with type 2 diabetes do not take their medications as prescribed, according to a new research review published in Diabetologia in November 2025. Researchers examined existing studies on medication adherence, including how often patients miss doses, why it happens, and what strategies may help. They estimated that about 38% of patients with type 2 diabetes are not fully adherent to their medications. Adherence rates vary depending on the type of medication. About 63% to 68% of patients take oral glucose-lowering drugs as directed, while adherence drops to 43% to 54% for injectable GLP-1 medications and 41% to 64% for insulin. Poor adherence can lead to serious consequences. One retrospective study cited in the review found that patients who consistently took their glucose-lowering medications had a 31% lower risk of hospitalization or emergency department visits. The review also highlighted ways to improve adherence. Simplifying medication routines can help, such as using fixed-dose combination pills, which combine multiple drugs into a single tablet. Studies show these combinations are linked to better adherence and improved blood sugar control. Pharmacists can also play an important role by providing education, reviewing medications, setting up reminders, and helping patients organize their treatment plans. The researchers noted that support should be tailored to each patient. Older adults may benefit from simpler systems and caregiver support, while younger patients may respond better to digital tools like app-based reminders. The authors also found that measuring adherence is challenging and recommend using multiple methods, such as pharmacy records, patient interviews, and objective tests when possible. Overall, the review concludes that personalized, multi-step approaches lasting at least three months are most effective in helping people with type 2 diabetes stay on track with their medications. https://www.pharmacytimes.com/view/type-2-diabetes-medication-adherence-rates-remain-low-and-pharmacists-can-help XX New clinical trial shows metformin does not directly reverse insulin resistance in people with type 1 diabetes. Instead, it lowers the total amount of insulin required to keep blood glucose levels within the recommended range. The findings, published in Nature Communications, challenge long-held assumptions about how metformin works in type 1 diabetes. The results may help physicians refine treatment strategies and reduce the daily demands placed on people who rely solely on insulin therapy. "Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes," says Dr. Jennifer Snaith, endocrinologist and co-lead of the study. https://scitechdaily.com/groundbreaking-trial-reveals-unexpected-benefit-of-metformin-in-type-1-diabetes/ Tech news ahead, including updates from Sensonics, Dexcom & Tandem.. right after this…. Back ot the wnews.. XX Sensonics shares that it's secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in the second half of 2026. Gemini builds on the implanted CGM to put the transmitter under the skin as well as the sensor. https://www.drugdeliverybusiness.com/senseonics-q4-2025-ide-gemini-cgm/ XX Medtronic Diabetes is now officially MiniMid, a stand alone public company. Medtronic acquired MiniMed 25 years ago announed last May that it would spin its diabetes business off. In their statement the company points out that MiniMed is the only diabetes tech company to sell both insulin pumps and continuous glucose monitors. https://www.investing.com/news/stock-market-news/medtronics-diabetes-unit-minimed-valued-at-53-billion-as-shares-fall-in-nasdaq-debut-4547518 XX Kevin Sayer heads back to Dexcom.. The former CEO is back in his position as executive chair of the Board, he'd stepped away for a medical leave. Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer's return to the board comes just days after Dexcom announced a new board member. Last week, the company announced that it added Google SVP, Platforms and Devices, Rick Osterloh, to its board as well. https://www.drugdeliverybusiness.com/kevin-sayer-returns-dexcom-board-chair/ SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement. Osterloh serves as Senior Vice President, Platforms & Devices at Google, where he oversees Android, Google Play, Chrome, and Google's hardware portfolio including Pixel phones, Google Nest devices, and Fitbit wearables. He has held this position since 2016. https://www.investing.com/news/company-news/dexcom-appoints-google-executive-rick-osterloh-to-board-93CH-4529662 XX Sequel Med Tech announced broad national availability of its twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. After U.S. FDA clearance in 2024 and a controlled launch to optimize the twiist experience, the system is now fully available nationwide. The release says: Built on Sequel's proprietary iiSure™ Technology, the system enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems1, potentially reducing the risk of unexplained high glucose and giving you time to take action before experiencing severe high blood sugar or DKA2. Designed to expand access to automated insulin delivery, twiist is available through pharmacy channels with a flexible access model, XX Tandem Diabetes Care's Mobi automated insulin delivery system is now available with Android devices. In November, Tandem announced that it received FDA approval for the Android version of its Mobi mobile app. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year. Tandem launched Mobi in the U.S. in February 2024. It initially received FDA clearance for people with diabetes ages six and up in July 2023. The system then received expanded clearance for pediatric indications in April 2024, then later won CE mark in May 2025. Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the flagship Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve. https://www.drugdeliverybusiness.com/tandem-diabetes-care-launches-mobi-android/
Armed with nothing more than a name and an old family photo, Lexie goes on the hunt to find her biological father. And when she finds him she realizes she has a secret she can't share with him. It's a complicated story of family, secrets and broken trust. DAILY LOOK For 50% off your first order, head to DailyLook.com and use code SECRETROOM. HERS Thank you, HERS! Go to forhers.com/SECRET for your personalized weight loss treatment options. Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. WILD GRAIN Get $30 off your first box + free Croissants in every box. Go to wildgrain.com/SECRET to start your subscription. PICTURES See pictures of Lexie, her family and fiancee. They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED If you are in love with Lexie, and who couldn't be at this point, she's back in one week to talk about what it was like to share her finally secret. She also tells us her max meet-cute story of how she met her fiancee. There's a free trial for the show, after which we hope you'll stay on as a supporting member, because the Secret Room is a listener supported show. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See our sponsors and their offers: secretroompodcast.com/codes
How could Lexie not know that she was black? And when the secret was revealed it nearly shattered her world. It's a complicated story of family, secrets and broken trust. DRIP DROP Get 20% off your first order: dripdrop.com and use promo code secret. HERS Thank you, HERS! Go to forhers.com/SECRET for your personalized weight loss treatment options. Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. MINT MOBILE Get unlimited premium wireless for just $15 per month. Make the switch! MINTMOBILE.com/SECRET WILD GRAIN Get $30 off your first box + free Croissants in every box. Go to wildgrain.com/SECRET to start your subscription. PICTURES See pictures of Lexie and her fam now. Also see the the picture of Lexie's mom and her bio dad her grandfather showed her They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Deja, like Lexie on today's show, is black and raised by white parents. But her experience was different. On the outside she seemed like the perfect pastor's kid. But her secret was that on the inside she was living in conflict with everything she was taught and never knew how to make all of those pieces fit together. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
What happens when grief doesn't just visit once—but keeps coming back? In this deeply honest conversation, Vanessa May shares how she navigated losing her son Harry, then her husband Anthony, and father during the pandemic, all while battling COVID and later a cancer diagnosis.Vanessa doesn't sugarcoat. She doesn't spiritually bypass. She tells the truth about what it's like when the ground keeps getting ripped out from under you—and how she's found her way forward anyway.In this episode, we explore:The unique pain of compounded grief—losing a child and a spouseHow trauma lives in the body and can manifest as illnessWhy "resilience" can feel like pressure instead of praiseSoul planning, earth school, and making meaning from lossThe loneliness of widowhood in the middle yearsHow Vanessa still feels Harry and Anthony guiding herThe six women featured in her new book and what they have in commonFinding the balance between spiritual hope and raw human griefAbout Vanessa May:Vanessa is a holistic grief coach, certified grief educator, nutritional therapist, and author of three books including Love Untethered: How to Live When Your Child Dies and her newest release, When Grief Takes Everything: A Survival Guide to Devastating Loss.Connect with Vanessa:Website: VanessaMay.co.ukInstagram: @may.wellbeing.griefsupportWhat resonated with you in this conversation?I'd love to hear your thoughts. Join the discussion at grief2growth.substack.com, leave a comment, and connect with others walking this road.Visit the Grief 2 Growth store for FREE items as well as other tools to help you along your journey:Guided MeditationsMy book GEMS of Healing (signed copy)My Oracle deck to help you connect with your loved onesMini-coursesMini-guidesCheck it out at https://grief2growth.com/store Grief doesn't follow stages, timelines, or rules.If you've ever wondered, “Am I doing this right?”—you're not alone.That's why I created the Grief Check-In. It's not a test. There are no right or wrong answers. In just a few minutes, you'll gain clarity, reassurance, and language for what you're experiencing.
When the FDA removed GLP-1s from the shortage list, many were unsure whether compounded versions could still be prescribed. In this episode, hosts Brad and Michael share the story of a medical weight loss clinic and the fallout after these drugs were removed from the shortage list. Tune in to learn how regulatory shifts, misinformation, and risk management collide in modern medicine. Find out how practices can navigate evolving regulations and avoid pitfalls when prescribing compounded weight loss drugs.Chapters00:00 Intro 00:50 Banter 04:34 Story 17:18 Access+ 17:48 Legal Takeaways 30:07 OutroWatch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadatto Stay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn
Join us for bonus stuff every week at https://www.patreon.com/timbutterly check out Ehsan Ahmad's Special: https://youtu.be/m6weMUz0lqA?si=9UbbaInn4vDXroBS Subscribe to the channel for more from Tim Butterly. UPCOMING SHOWS AT https://timbutterly.com Catch new eps of Metal Girl Solid live - https://www.twitch.tv/timbutterly For a limited time, fans get 60% off FOR LIFE & 2 Free Gifts at Mars Men when you use code TBS at https://mengotomars.com/ Download Cash App Today: https://click.cash.app/ui6m/ijd4q5z4 #CashAppPod.Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. See terms and conditions at https://cash.app/legal/us/en-us/card-agreement. Direct Deposit, Overdraft Coverage and Discounts provided by Cash App, a Block, Inc. brand. Visit http://cash.app/legal/podcast for full disclosures. Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review by the FDA. For full safety information, go to https://ro.co/safetyinfo
On this episode of RawTalk, Bradley Martyn sits down with Cono and talks about saving his podcast with Brad, responding to industry plant accusations, turning rage bait into a business, quitting steroids, manifestation, landing a song with Post Malone & much more!Sponsored by: Rugiet Go to Https://www.rugiet.com/RAWTALK for 15% off your first order!*Individual results may vary with prescription treatment. Compounded drugs are permitted to be prescribed under federal law, but are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review. Please visit the Rugiet website for full safety information.*Sponsor RAWTALK: https://public.liveread.io/media-kit/rawtalkSUBSCRIBE HERE: https://www.youtube.com/c/REALRAWTALK?sub_confirmation=1LISTEN ON APPLE PODCASTS: https://podcasts.apple.com/us/podcast/rawtalk/id1294154339FOLLOW RAWTALK PODCAST:INSTAGRAM | https://instagram.com/getrawtalkTIKTOK | https://tiktok.com/@askrawtalkFOLLOW BRADLEY:INSTAGRAM | https://instagram.com/bradleymartynSUBSCRIBE TO RAWTALK PODCAST CLIPS: https://www.youtube.com/channel/UCvzSBNBOK599FqzrTZS8ScQ/?sub_confirmation=1SUBSCRIBE TO LIFE OF BRADLEY MARTYN: https://www.youtube.com/channel/UCWTQG2aMDYKGDqYEGqJb1FA/?sub_confirmation=1SUBSCRIBE TO FITNESS CHANNEL: https://www.youtube.com/bradleymartynonline?sub_confirmation=1RAWGEAR: https://www.rawgear.com (CODE:RAW)
In our last episode, "I Robbed a Subway Sandwich Store," Kat tells how she got tangled up in the robbery of a sandwich shop one hair raising night. Today our subway sandwich robbing heroine Kat is back with the high octane conclusion of her story. Part 2 opens with a bang. Literally. Listen to find out how Rachel's car blows up after the high speed car chase that ensued after the robbery. DAILY LOOK For 50% off your first order, head to DailyLook.com and use code SECRETROOM. DRIP DROP Get 20% off your first order: dripdrop.com and use promo code secret. HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOMECHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. PICTURES See Kat, Rachel, Chris, Janice and the subway right now! They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Gabi moves to the US on a student visa to go to a university, but her visa status is tied to her GPA. She ends up making some very poor decisions that put her visa in jeopardy and she's got to get creative to keep everything from blowing up in front of her parents. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See this week's sponsors and their offers at secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
OB419: Compounded Lostness Released to show supporters on 1/6/2026 Public release scheduled for 1/20/2026 Have a great week, and thanks for listening to Opposing Bases Air Traffic Talk! ✈️ Real pilots. Real controllers. Real talk.
One drunken afternoon Michelle's girlfriend confessed to a murder. The circumstances surrounding the killing were darker than she could imagine, and it's turned her life upside down. DRIP DROP Get 20% off your first order: dripdrop.com and use promo code secret. HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. PICTURES See pictures from Michelle's story.They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before any of your favorite gym bros were talking about Retatrutide. We were talking about Reta, who tried Retatrutide here at On The Pen. And that's because we identified this triple agonist as a game changer among game changers. So This is going to be a very Retatrutide heavy episode, and so I hope you'll join us and stick with us if this is a topic you enjoy, because I think this is really going to effectively lay the groundwork for what accessibility to this medication will look like. So let's get into it. Welcome to the On The Pen Podcast with your host, Dave Knapp. Welcome to the On The Pen, the weekly dose podcast. This is our weekly roundup in incretin memetic news. And frankly, there's no news that is bigger than Reta-Trutide news. Just find me any news that is bigger than the data that we got on Reta-Trutide. Now, we already did a video about the Triumph Phase II clinical trials that we got in osteoarthritis of the knee. You can go back and check out that video if you'd like more data. So we're not gonna super... rehash the data. We'll go over at a high level what the data showed us. We're not going to go over how the medicine works, because by now we all know that it's the triple agonist, right? If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat. It is absolutely revving up people's metabolism and showing a tremendous amount of weight loss. So let's get into what the weight loss looked like in this first trial, because there are longer obesity trials where, where the primary outcome is the weight loss this was again a specific trial in measuring pain reduction in folks with osteoarthritis of the knee but check out these numbers these are placebo adjusted meaning it's taking the two percent out that people lost on placebo but looking at these numbers Folks on one milligram over forty eight weeks lost seventeen percent. They bumped up to four milligrams. Those folks lost twenty two percent. So right there at the lowest dose, you're already reaching the efficacy of today's drugs that are on the market, like triseptide and semaglutide in their various forms. If you bumped up to eight milligrams, you saw twenty four percent placebo adjusted weight loss and at twelve milligrams, twenty six point four percent weight loss. Adding back in that two percent of the placebo that those on placebo loss, that's twenty eight point four percent weight loss in these forty eight weeks at the highest dose. When you adjust for some of the more real world outcomes, you kind of ding the numbers a little bit based upon people who quit the drug, et cetera. Those numbers look more like a twenty percent weight loss and twenty three point seven percent weight loss at the highest dose. But even then, you're still seeing a drug that is better than the current drugs that are on the market. around forty eight percent of patients on Retatrutide lost greater than twenty five percent. And then if you were at that twelve twelve milligram dose, that highest dose patients lost fifty nine percent of patients lost more than twenty five percent of their body weight. There was a subset that lost thirty percent of their body weight and some even over thirty five percent of their body weight on Retatrutide. So the lower doses compete with today's best drugs and the upper doses are entering into bariatric surgery level weight loss. And that's putting the whole obesity system on notice and probably a lot of surgeons nervous because typical body weight loss was something like the street sleeve gastrectomy. For example, it's about eighteen to twenty five percent body weight. The Roux-en-Y gastric bypass twenty five to thirty five percent weight loss or the duodenal switch thirty to forty percent weight loss. So the upper doses of Ritutrutide overlap with sleeve and bypass outcomes without any surgery. It's incredible. It is a game changer among game changer. It is the new benchmark in obesity medicine. And there's actually more data, like I said, landing in later twenty twenty six. The longer duration will historically, if history is a marker, equal more weight loss than we even see here at this forty eight weeks. We have an interview that will be airing later this week on our channel and on our podcast with our friend Mimi from Australia who just wrapped up her clinical trial on Retatrutide. They ended it like ten weeks early on her, which was a huge bummer to her. So we're going to hear from her because she had to end abruptly. We're going to hear her story, an incredible story. She's one of those folks that got up that thirty five percent body weight loss in the time that she was on Retatrutide. So, this is just showing you that these drugs are not simply an alternative to bariatric surgery. We are approaching a point in time where these are on par with bariatric surgery, and as people are on this Reta-Trutide trial, you see that these numbers aren't plateauing either. So we will see stronger weight loss numbers the longer that these folks are on this trial. And I think you'll see some of those numbers in that population of folks on the higher doses eclipse maybe even some of what we see with some of these bariatric surgeries. the real story that i think is taking shape here is not in how powerful Retatrutide is because we've literally been expecting or anticipating this kind of data for more than three years at on the pin we've been talking about this and i think that's sort of reflected in the fact that you didn't see this massive spike in eli lilly stock wall street was expecting this as well Um, so it was on par, I think with expectations, but the expectations are astronomical compared to previous options that were available to patients and all the innovation in the world. All of these drugs, we talked at last week about WV, E double Oh seven, the James Bond of weight loss that targets fat, not only targets fat loss, but it also targets the promotion of building of, of lean muscle mass. We're talking about an insane future in obesity medicine. But none of it means anything if people can't access it. And that's really where we are today in terms of ensuring that there's going to be an option for everyone. And that's sort of what I want to get into today, because Lilly wants Retatrutide to be classified as a biologic, so not a traditional small molecule drug like you've seen every other incretin and nutrient-stimulated hormone-treating obesity on the market to date. They're trying to get this classified as a biologic. Now, we talked about this before on the podcast. That matters in three major ways. It affects the exclusivity length of time that a pharmaceutical company has on a drug. That goes from, I believe, five years of market exclusivity to twelve. It affects compounding rules because biologics cannot be compounded. And then that gives the pharmaceutical companies a tremendous amount of pricing power in the marketplace, because essentially there's no competition and there's no competition for a long time. But this whole argument about getting this classified as a biologic is not about safety. It's about protection and we're going to get into it. So let's explain this here. This is why Retatrutide really is not a biologic arguably. So biologics are large proteins. There are hundreds of or even thousands of amino acids grown in living cells that are sensitive to tiny manufacturing changes. Retatrutide is a short chain peptide. It's chemically synthesized and it is below the traditional biological size thresholds when it comes to how those things are defined. We'll just leave it at that. So even though it acts like a biologic in the body, it's made like a drug. It's made like a small molecule drug. And if it's treated as a drug, they get, like I said, five years of market exclusivity. Now, really a lot of confusion around what this means, but essentially the first five years of the life of a drug, the patent can be challenged for a number of reasons. We've seen patent challenges right now are going on in the courts for both semaglutide and terzepatide. But these companies are guaranteed that five years of market exclusivity, no matter how those patent lawsuits shake out. That five years jumps to twelve years with the biologic. So ultimately, there's no biosimilars that are allowed during that twelve year window. Again, with terzapatidin and semaglutide, it's five years. They could lose their market exclusivity within five years of the release of the patent. twelve years with a biologic. So if they lose their patent challenges on Trezabitide, they still have some time left with market exclusivity for the drug. They likely will not lose those, but that jumps to twelve years. And I think the most important thing to understand about the reclassification of Reta-Trutide to a biologic would mean that, 503A and 503B pharmacies are effectively locked out of compounding this medication, 503Bs would have some latitude arguably, but they would face extreme barriers. Routine compounding becomes legally and technically restricted because biological status doesn't slow compounding down. It actually shuts the door or almost completely shuts the door. Biologics not only would allow Lilly to have longer market exclusivity, no compounding, but it would allow them to command a higher price in the marketplace because A, they get this designation and there's an assumption when they bring this to market that they're harder to manufacture, that they're harder to copy, that there are fewer negotiating alternatives for payers. They can command a higher price with the insurance companies, and the price pressure stays muted for much longer because, again, you don't have those pressures of compounding. You don't have the pressures externally from lawsuits that could end your market exclusivity in that first five years of the drug's existence. So there's just a lot of price pressure upwards on a biologic compared to a normal small molecule drug. And when there's no credible alternative or backup option, which to Retatrutide, there wouldn't be, it'd be the first drug that has bariatric surgery level results. The prices won't come down. They'll command a massive price and the prices won't come down. So let's talk about where this currently stands because ultimately the Eli Lilly went to the FDA. We've been covering this for well over a year, maybe close to two years now, a year and a half at least. Lily went to the FDA, they said, we want this classified as a biologic, here are the reasons why. The FDA initially said, no, we're not gonna do that. So Lily challenged that decision in court. So the point that we're at today is the court told the FDA to reconsider and better explain itself So the first no given to the FDA to Lilly didn't stick. The courts looked at it and they said, you need a better, you need to reconsider your decision and you need to explain your decision better to Lilly. So ultimately we're sitting now at the point where the court has made its decision that the FDA has to go back and now we await basically what the FDA has to say on this. But if this thing is classified as a biologic, that would be a massive massive loss for patients. Now, again, we're, we're focusing on the accessibility of this drug into the future. And, and I think that this is an important conversation to have. One of the interesting points that I have to bring into the conversation is the fact that I got to sit in on a, on a closed session question and answer with the media. I didn't get to answer or, excuse me, excuse me, ask a question at this time, but shortly after the most favored nations announcement, with eli lilly and the trump administration in the oval office that day there was a press briefing that i was invited to dave ricks was asked by max bayer reporter of endpoints who we've interviewed here on this very podcast and he was asked was Retatrutide included in the most favored nations discussions meaning will we get a cash pay version of Retatrutide uh that is you know circumventing the pbms uh will we get these cheaper prices will will it be be two hundred fifty dollars also and there was a hard no there was a hard no like no that was not included that was not part of these discussions even though what we heard from the trump administration was that those these companies that were jumping on to the most favored nations agreement were also agreeing to offer future drugs at most favored nations pricing now was lily saying that no they're not going to offer it at the it wasn't part of the negotiations in terms of the price points that they had discussed for triseptide maybe or did it mean altogether there won't be a cash pay option of this medication i don't know um that we would love to get clarity on But I highly doubt we're going to get any more information than necessary at this point in time. So, Reta-Trutide is being positioned to be a drug that, and well so, should be offered at a premium. This is a drug that is far exceeding the current drugs that are on the market. I think that we're gonna see even the indications of Reta-Trutide far beyond simple obesity, but it is going to be their crown jewel for the next decade, more than likely. Reta-Trutide is going to be a massive drug, and so they're attempting to build a moat around it. And these are things that we need to be aware of as a community so that we can hold our positions and conversations about these and basically, you know, be able to articulate to people in positions of power like this is an important thing to us. This is an important thing in the advocacy of obesity and sort of the next frontier of the fight of accessibility, which marches on. each and every day because of course the current drugs, while as great as they are and as much as access is expanding, there are still people with sicker or rather more advanced versions of metabolic disease that are gonna need these newer treatments and price is going to be a huge factor. So let's talk about the gray market right now because I think it's also nearly impossible to talk about this topic without including a discussion about the gray market because there are, as I mentioned at the outset, hundreds of thousands of people on this medication already. So research grade Retatrutide exists. It's in the gray markets of the Internet. It's where people are going and they're buying, you know, basically versions of these these peptides that are made in factories overseas. They're being imported into the United States, oftentimes illicitly in shipments that are marked as something else. The FDA has tried to crack down. There's no doctor involved in this. It's a very, that's why it's called the gray market, right? So it's not a prescription medicine, but the demand for this is massive. And all you have to do is really scroll your TikTok for about fifteen minutes. You're going to come across a insane amount of content on the topic of Retatrutide. An insane amount of, and oftentimes, you know, what I find most disturbing is oftentimes it looks like very young people. very young people taking Retatrutide. Crazy, it's crazy. But the demand is massive and there's a whole gray market for it proliferating over on TikTok and in the far reaches of the internet. And I would estimate that tens, if not hundreds of thousands of people are already or have already used it. And I think it's a testament to a to to the effectiveness of this drug. It's also a testament to the fact that there needs to be more guardrails, I think, around this stuff than there currently is, because gray markets appear and they thrive when legal access lags the reality of the demand for the medication. And you saw this earlier this week as we launched a petition to fight back against the Safe Drug Act of twenty twenty five, a drug, a drug act that is in theory designed to put guardrails around compounding. But in practice, I think is creating a new battlefield for Eli Lilly and Novo Nordisk to shut down compounding on the current classes of medications, which is why We as a community need to be loud about our opposition to it. If they were really concerned about the safety of compounds, they would do two very simple things. They would require reporting around the active pharmaceutical ingredient of a compound. Patients ought to be able to know where the actual source of their medication is coming from. And they should know that those places are FDA approved and inspected. And the second thing is they should require adverse event reporting. Those are required of 503Bs. They should be required of 503As as well. 503As are making a tremendous amount of money. They're making thousands and thousands of these scripts. So when there are adverse events, they should be required to report those to the FDA. Simple. None of that is in this bill. None of it. None of it. Instead, it seeks to put caps on the amount of compounds that can be made by a compound pharmacy without them having to report to the FDA. And then it seeks to codify the definition of essential copy. Again, all of these things that will become law and then argued in court and then a battlefield for Lilly to potentially win a legal battle and thwart compounding. It's creating a new battlefield for them. They're losing in the courts. They're losing with the current language that exists in the Food, Drug, and Cosmetic Act. So we create new language. We create new law. Just vague enough to pull some threads and hopefully win something in court. That's how I see it. You may see it differently. If you do, curious to hear from you. But if you want to fight back against this legislation, you can go to otplinks.com and fight back against that. piece of legislation, because I think that we need as a community to have our voices heard on this, especially those who have gotten healthier by way of compounded medications. So the rumor on the gray market, to get back and close the thought loop here, There's been no specific FDA cutoff announced, but what the rumors going around are that that the compounded versions of GLP ones, especially obesity medicine in the gray market, are all going to turn off like a sieve on January first. Now, I seem to feel like this is probably more of a marketing tactic by these companies to sell a whole bunch of peptides at the end of the year. I think that's probably creating some panic and probably panic buying on people's parts. And so these companies are benefiting greatly. Again, that's why there should be guardrails around this. There's no guardrails around this at all. I mean, at the end of the day, they can say whatever they want to say, so long as they cloak everything in research grade. And these rumors proliferate around and people spend thousands, tens of thousands of dollars. I've heard of people having twenty years worth of Retatrutide in their freezer. Why? For what purpose do you need that? So just a massive amount of money made in this gray market. And that's not to knock people who use it. I say this all the time, but I think it's worth qualifying the statement. It's not knocking people who use it. I get it. But at the same time, we're talking about an industry that is, there's no altruism here. They're in it for money just as much as Eli Lilly is, except they have actually done nothing in the way of advancing medicine. They've just taken intellectual property, copied it, and sold it to you with a label that says, don't put this in your body. So you know where I stand on the gray market. I've heard from many people who've been injured by gray market stuff. It's just what it is. It's a gray market. You're taking your health into your own hands. Please, whatever you're doing out there, as risky as it may be, please involve your doctor and let your doctor know what you're doing so you can be monitored for the things your doctor believes you should be monitored for if you're using this. But this all underscores, again, the need for accessibility to these medications, the need for us to be aware of the fact that a moat is already being built around the most advanced metabolic drug in the pipeline. And we just need to be aware so that when it comes time to fight, we're all ready and informed. And that's what this podcast is serving to do. Before we jump into the next topic, I do want to thank our sponsor, our headline sponsor of this podcast. is a company called Shed. Now, if you are looking for access to care for obesity, then look no further than our partners at Shed who believed in this podcast enough to help us do it full time. You can go to Trished.com and use code OTP25 to save twenty five percent at Trished.com, where you're going to get connected to a doctor who will when medically necessary prescribe medication to treat your obesity. You also get access to coaching. You'll get access to all sorts of medication, whether it's the branded or the compounded versions, depending on your specific situation. All of it is available at Trished.com. They use one of my favorite compound pharmacies in the game, Strive Pharmacy, which I've gotten the chance to dig into on my own. I really love what they do there. They're a It functionally operates a lot more like a 503B. Uh, and I think that they're doing great work over at a strive pharmacy. They partner with shed. So I just love this, this, and when we were looking for somebody to offer a compounded versions, I wanted to make sure that I trusted the pharmacy. People always ask me, Dave, who, who should I go to? I'm like the pharmacy matters more than anything because you want to trust the source of your medication. So try shed.com use code OTP25. Listen, you're going to want to learn about taking any new medication before you take it. Learn about the potential side effects. Learn about the trade offs. There's no free lunch, but all of the information that you're going to need, you can find it. Try shed.com and be familiarizing yourself with all of your options there. So thank you to Shed for being a wonderful partner here at On The Pen. Now let's talk about some data that dropped. We're talking about accessibility and all of the sort of advancements in the world mean very little if people can't access it. That's why I think this data that dropped this past week from our friends over at Rowe is incredible. Absolutely game changing data. So check out this data. Real world telehealth data looking at sixty eight weeks. This is looking at patients who were enrolled in their row body program and on a GLP one specifically some maglutide mean weight loss in this study looked at again patients in over sixty eight weeks. The mean weight loss was sixteen point six percent on average. Thirty three percent of patients lost more than twenty percent and the safety in this study and looking at this data match the clinical trials. So what we're seeing here is that care for obesity can be delivered through a telehealth platform at scale and match clinical trial results. So that scalability decides how many people get access. There are not enough doctors out there to serve the over hundred million people in the United States living with overweight or obesity. so when you hear these blowhard doctors online calling all telehealth platforms except their own a pill mill or as i like to say pin mill the data is actually showing something quite different in that this type of obesity care can be delivered at scale through telehealth platforms it can meet people where they're at and allow people to get care without the shame, without the stigma, without their doctor just pointing to the door and saying, if you want a GLP-I, get out of my office. I ain't going to get it here. How ridiculous. But these people can go to platforms like Rho or Shed or any number of telehealth platforms that are out there and not only get access to medicine, but get access to care. So of course, not all telehealth companies are created equal. Of course, not all compound pharmacies are created equal. You want to do your homework and all of that. But this is data that shows that This kind of care can be delivered at scale via a virtual platform and show similar results to a clinical trial. I think, and this is peer reviewed data, and I think that this is just absolutely great news because when we talk about the problem, we need scalable solutions. The old brick and mortar ain't going to work when you don't have enough doctors to serve enough patients. If we want to get life-changing treatments like ritatratide or terzapatide, semaglutide, whatever, into the hands of the people who need it the most, we need companies to innovate scalable tech platforms that can meet patients where they are, that can leverage current technologies to find people the care that they need. And in this case, it's access to a doctor. It's access to a platform. It's access to prescription medication when appropriately prescribed. And it can be done, and it is being done. So I think this is great news, and will play a huge part in the future. As we talk about Retatrutide, even though it's a year and a half away, maybe a little bit longer, it's already exposing – the issues around accessibility and pricing. Hopefully there will be compounded versions available if they're medically necessitated, if there are shortages. We hope that the battleground for that is not already set and won by Lilly before this drug even comes to market. But there are strategies being done to keep people boxed out But I can tell you that whatever happens with Retatrutide, the future of obesity medicine is in virtual care. And platforms are rising to the occasion. Retatrutide hasn't reached patients yet, but it's already forcing the system to show us, you know, are you ready? Are you ready to deliver bariatric surgery level results at scale to the people who need them? So I am so thankful that you joined me here on this podcast today. Again, we love to talk about we're at a Retatrutide. If you're interested, we've been going live every Monday, Wednesday and Friday at eleven a.m. Central Time here on our YouTube channel, on our tick tock, on our X platform. We're doing that because there's enough news to bring you just about every single day. And we've been doing it for the last couple of weeks. If you've enjoyed it, let me know in the comments of the video on YouTube. Send me an email at David on the pen dot com. Uh, so every single Monday, Wednesday, Friday, and then we do a weekly rundown of the obesity medicine news every Tuesday. That's what this is. The weekly dose podcast. You can catch this on all of the platforms that you listen to your podcasts on, and please make sure to leave us a five star rating and review before you log out of your podcast app. That helps so much. I don't think you guys understand how much that helps, uh, the work that we do here to just train the podcast algorithms that this one is worth listening to. I hope you enjoyed today's podcast. If you did, drop it a thumbs up, five-star review, subscribe on YouTube, do all the things. Thank you for being here, and thank you for being the best part of what we do. We will catch you on the next one. Thank you, my friends. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Stephanie Batliner, VP of Regulatory Affairs and R&D North America for Bimeda, joined us to discuss the FDA approval process for pioneer and generic animal drugs. She also discussed veterinary devices, pharmacy compounding, counterfeit drugs, and more. This episode of Disease Du Jour is brought to you by Bimeda.GUESTS AND LINKS - EPISODE 171Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Stephanie Batliner, VP of Regulatory Affairs and R&D North America for BimedaPodcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Bimeda.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)
In Part 1 of her story (I Sold My Body to Save My Horse) Nikki turned to the oldest profession in a desperate bid to survive. Now she searches for stability while facing new crises that imperil not only herself but her horse. DRIP DROP Get 20% off your first order: dripdrop.com and use promo code secret. HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. PICTURES See pictures of Nikky and her horse! They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE The Secret Room is now on YouTube! THE SECRET ROOM | UNLOCKED Siobahn lives a picture perfect, white picket-fence life … she's married with three kids, and has all the things you're supposed to want. But underneath she's kept a secret: a longing for something out of reach. Siobahn's always been attracted to women, and has never taken the chance to fully explore her true self. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
Chris Cuomo responds directly to a flood of viewer comments and questions — from accusations that he's “changed,” to criticism of his Alan Dershowitz interview, to claims that he's too hard or too soft on Trump. He addresses confusion around shutdown politics, breaks down the realities of the ACA debate, and pushes back on misinformation about what Trump did or didn't do — including his shifting claim about “ending seven wars.” Cuomo also explains why outrage remains the dominant political currency online, and why so many people mistake anger for clarity. Cuomo digs into arguments about wealth, privilege, and independence; clarifies his views on Epstein, Venezuela, and selective outrage; and calls out how social media's algorithmic incentives twist honest disagreement into hostility. He talks openly about intensity, decency, and why provocation has replaced persuasion — and closes with a reminder not to waste moments with family on fights that don't matter. Follow and subscribe to The Chris Cuomo Project on Apple Podcasts, Spotify, and YouTube for new episodes every Tuesday and Thursday: https://linktr.ee/cuomoproject Join Chris Ad-Free On Substack: http://thechriscuomoproject.substack.com Support our sponsors: Exclusive $45-off Carver Mat at https://on.auraframes.com/CUOMO Promo Code CUOMO Ready to give Rugiet a try? Get 15% off your first order by going to http://rugiet.com/CUOMO and using code CUOMO. Disclaimer - Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com. Don't miss NOBL's biggest Sale of the Year! Head to http://NOBLTravel.com for up to 62% off your entire order! #NOBL #ad Learn more about your ad choices. Visit podcastchoices.com/adchoices
Senator Rand Paul (R-Kentucky) joins Chris Cuomo to break down why the fight over the Epstein files has become a test of public trust — and why he supported full disclosure even while warning people not to expect bombshell revelations. Cuomo presses Paul on how Washington keeps feeding suspicion through secrecy and mixed messages, what real accountability would look like, and why both parties are too comfortable letting the public assume the worst. They also dig into the surprise hemp ban buried in the shutdown bill, Paul's clashes with Mitch McConnell over industry pressure, and how a $25 billion sector got kneecapped without a real debate. From Venezuela to war powers to the politics of fear inside Congress, Paul explains why he believes leaders in both parties are avoiding tough choices as the country drifts deeper into dysfunction. Follow and subscribe to The Chris Cuomo Project on Apple Podcasts, Spotify, and YouTube for new episodes every Tuesday and Thursday: https://linktr.ee/cuomoproject Join Chris Ad-Free On Substack: http://thechriscuomoproject.substack.com Support our sponsors: For a limited time, our listeners are getting an additional $20 Off with code TAKE20. Head to Superpower.com and use code TAKE20 at checkout for $20 off your membership. Take advantage of Soul's Black Friday-Cyber Monday deal now! For a limited time, get 40% off your entire order! Go to http://GetSoul.com and use the code CUOMO. Ready to give Rugiet a try? Get 15% off your first order by going to http://rugiet.com/CUOMO and using code CUOMO. Disclaimer - Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices
In this episode of The President's Daily Brief: Newly uncovered emails reveal Jeffrey Epstein's sprawling network of foreign contacts — and his extraordinary claims that he was feeding Russian associates insight into Donald Trump's policy decisions. Poland deploys security forces after a critical rail line to Ukraine is blown up in what officials are calling a suspected act of sabotage. Plus — thousands of demonstrators in Mexico City clash with police during protests over cartel violence and government inaction. And in today's Back of the Brief — a notorious Ecuadorian drug kingpin who faked his own death has finally been captured in Spain, ending four years on the run. To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting https://PDBPremium.com. Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going to http://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at https://Rugiet.com Lean: Visit https://BrickhouseSale.comfor 30% off StopBox: Not only do you get 10% Off your entire order when you use code PDB10 at https://stopboxusa.com/PDB10, but they are also giving you Buy One Get One Free for their StopBox Pro. #stopboxpod Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of The PDB Afternoon Bulletin: Russia's oil sector is taking heavy hits on two fronts. Ukrainian drones are striking deep inside the country, while new U.S. sanctions are cutting off key buyers in India and China. We'll explain why this dual pressure is becoming a serious problem for Moscow's war economy. Germany is preparing to lift its freeze on arms exports to Israel, saying the Gaza ceasefire has stabilized enough to reverse restrictions imposed during the height of the conflict. Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going to http://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at https://Rugiet.com Lean: Visit https://BrickhouseSale.comfor 30% off StopBox: Not only do you get 10% Off your entire order when you use code PDB10 at https://stopboxusa.com/PDB10, but they are also giving you Buy One Get One Free for their StopBox Pro. #stopboxpod Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of The PDB Afternoon Bulletin: First—U.S. and Israeli officials say they've foiled an Iranian plot to assassinate Israel's ambassador to Mexico. It's just the latest episode in Iran's shadow war on the west, one that now stretches across the globe. Later in the show—The Kremlin's war machine is running low on soldiers — and now it's looking to Africa to fill the gaps. We'll examine reports that more than a thousand African fighters are on the frontlines in Ukraine, and what it says about Russia's growing desperation. To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting PDBPremium.com. Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going tohttp://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com. Birch Gold: Text PDB to 989898 and get your free info kit on gold Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of The President's Daily Brief: First—a UK intelligence report is detailing the staggering losses Russia's military has suffered in Ukraine, putting the number of casualties at more than 1.1 million. But Putin's bloody war of attrition continues, as his forces move closer to capturing the battered city of Pokrovsk. Later in the show—In a major test of the Gaza ceasefire deal, the Trump administration is reportedly pressuring Israel to allow safe passage for up to 200 Hamas operatives currently holed up in a vast tunnel network, provided the terrorists pledge to disarm. Plus—we're learning more about the ISIS-inspired terror ring behind a foiled plot in Michigan, as authorities bust two more suspects who were allegedly plotting a Boston bombing-style attack. In our 'Back of the Brief'—For the first time in 18 months, Somali pirates have successfully boarded a commercial ship, reviving fears of a return to hijackings in one of the world's most vital maritime trade routes. Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going tohttp://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com. Birch Gold: Text PDB to 989898 and get your free info kit on gold To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting PDBPremium.com.Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of The PDB Afternoon Bulletin: First—The deputy chairman of Russia's parliamentary defense committee claims the Kremlin has sent advanced air defense systems to the Maduro regime, while floating the possibility of also sending cruise and hypersonic missiles to Venezuela. Later in the show—Ukraine's intensifying drone campaign against Russian energy continues. Kyiv says Ukrainian drones struck a major oil refinery in Russia's Volgograd region for the second time in almost three month, while a separate strike set ablaze a major power plant deep in Russia's northeast. To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting PDBPremium.com. Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief American Financing: Call American Financing today to find out how customers are saving an avg of $800/mo. NMLS 182334, https://nmlsconsumeraccess.org . APR for rates in the 5s start at 6.196% for well qualified borrowers. Call 866-885-1881 for details about credit costs and terms. Visit http://www.AmericanFinancing.net/PDB Birch Gold: Text PDB to 989898 and get your free info kit on gold Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going tohttp://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of The President's Daily Brief: First—Syria's new president, once part of a jihadist insurgency, is set to meet President Trump at the White House on Monday. We'll break down what's at stake for U.S. policy, and why the administration is pushing both Congress and the UN to repeal heavy sanctions ahead of the meeting. Later in the show—South Korean intelligence has assessed that a summit between President Trump and North Korean dictator Kim Jong Un will likely take place next year, saying the hermit kingdom is already preparing behind the scenes for a dialogue. Plus—Russian strongman Vladimir Putin orders top officials to prepare plans to resume nuclear testing, a response to President Trump's recent announcement that the U.S. will soon begin nuclear testing for the first time in more than 30 years. In our 'Back of the Brief'—Ukraine's drone pilots are reportedly engaged in video-game-style kill-tracking, earning rewards for each successful strike on Russian forces. We'll break down this incentive-based system, and how it has fueled Ukraine's intensifying drone campaign. American Financing: Call American Financing today to find out how customers are saving an avg of $800/mo. NMLS 182334, https://nmlsconsumeraccess.org . APR for rates in the 5s start at 6.196% for well qualified borrowers. Call 866-885-1881 for details about credit costs and terms. Visit http://www.AmericanFinancing.net/PDB Birch Gold: Text PDB to 989898 and get your free info kit on gold Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going tohttp://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com. To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting PDBPremium.com.Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Learn more about your ad choices. Visit megaphone.fm/adchoices
Natty's Secret Dog is a story that's as much about Natty opening her heart to a dog in need of a home as it is about the love she had for her ailing mom. What happens to mom and how that lead to her secret being revealed, is Natty's secret. HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. ONE SKIN Get 15% off OneSkin with the code SECRET at https://www.oneskin.co/#oneskinpod PICTURES See Natty, Ellie, mom and Natty's husband right now on social! They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Amber's mother was highly regarded in their community, the very embodiment of leadership and trust. But to Amber her mom was an entirely different woman, one who wouldn't protect her from from something terrible. No one would suspect how this respected leader and mom shaped Amber's childhood, the effects of which linger on well after her passing. I'm Susie Lark, join me in one week.Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
Sponsored by: HelloFresh Get your meals here: Https://www.hellofresh.com/RAWTALK10FMSponsored by: Rugiet Go to Https://www.rugiet.com/RAWTALK for 15% off your first order!Individual results may vary with prescription treatment. Compounded drugs are permitted to be prescribed under federal law, but are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review. Please visit the Rugiet website for full safety information.On this episode of RawTalk, Bradley Martyn sits down with Elijah Scott, one of the fastest-rising voices in country music. Elijah opens up about growing up in SoCal, surviving shootouts, and turning his pain into purpose through music. He talks about how his first viral TikTok changed his life, why he turned down a record deal, what it really takes to stay consistent in the social media era and much more!Hope you enjoy, see you next Tuesday!SUBSCRIBE HERE: https://www.youtube.com/c/REALRAWTALK?sub_confirmation=1LISTEN ON APPLE PODCASTS: https://podcasts.apple.com/us/podcast/rawtalk/id1294154339FOLLOW RAWTALK PODCAST:INSTAGRAM | https://instagram.com/getrawtalkTIKTOK | https://tiktok.com/@askrawtalkFOLLOW BRADLEY:INSTAGRAM | https://instagram.com/bradleymartynSUBSCRIBE TO RAWTALK PODCAST CLIPS: https://www.youtube.com/channel/UCvzSBNBOK599FqzrTZS8ScQ/?sub_confirmation=1SUBSCRIBE TO LIFE OF BRADLEY MARTYN: https://www.youtube.com/channel/UCWTQG2aMDYKGDqYEGqJb1FA/?sub_confirmation=1SUBSCRIBE TO FITNESS CHANNEL: https://www.youtube.com/bradleymartynonline?sub_confirmation=1RAWGEAR: https://www.rawgear.com (CODE:RAW)
Kara's in The Secret Room to answer the question: What happens when your mom moves her secret lover into the basement? HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET. PICTURES Kara shared pictures of herself, her mom, her sister and boyfriend! They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE The Secret Room is now on YouTube! THE SECRET ROOM | UNLOCKED Ella is back for the conclusion of her secret: her parents didn't tell her she had a deadly disease. After the devastating passing of her little brother from the same condition, Ella began to experience intense pain herself. She tells us about her bold journey that spanned two continents seeking the answers she couldn't get at home. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
Vanessa is the manager of a reputable research foundation, a wife and mom of two. She's also a convicted tri-state felon on multiple counts of identity theft and grand larceny. She even spent time in jail. Only thing, her job, friends and much of her family have no idea. What would happen if the truth came out? HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. MINT MOBILE Get this new customer offer and your 3-month Unlimited wireless plan for just $15 a month at MINTMOBILE.com/SECRET. YOUTUBE You can now listen to The Secret Room on YouTube! THE SECRET ROOM | UNLOCKED Vanessa's childhood friend Jessica will join host Susie Lark to share her take on Vanessa's secret through the lens of a close friend. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producers: Jessica Ruiz, Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
Hi friends, happy Wednesday! So you guys know I love dictators. And you ended up *LOVING* the Caesar episode… So it made me wonder what other, *older* dictators were out there who I assumed were boring but actually had these scandalous lives. And that's when I found out about a certain emperor we're gonna talk about today. Not only did he mass murder an entire group of people, but he *personally* killed just about everyone who got close to him. And you might think okay, typical bloodthirsty tyrant. Been there, done that. But … no. No one has ever matched this guy's freak. Some of the dictators we've talked about are actually failed artists. And then they take revenge on the world by taking it over. But this guy… it's almost like he didn't care about being in power at all. All he wanted to do was sing. And dance. And have insane orgies with eunuchs. But instead… he was forced by his mother to rule Rome. Today I am coming to you with the insane TRUE story of one of the world's first tyrants. This is the Dark History of NERO. I appreciate you for coming by, and tune in next week for more Dark History. I sometimes talk about my Good Reads in the show. So here's the link if you want to check it out. IDK. lol: https://www.goodreads.com/user/show/139701263-bailey ________ FOLLOW ME AROUND Tik Tok: https://bit.ly/3e3jL9v Instagram: http://bit.ly/2nbO4PR Facebook: http://bit.ly/2mdZtK6 Twitter: http://bit.ly/2yT4BLV Pinterest: http://bit.ly/2mVpXnY Youtube: http://bit.ly/1HGw3Og Snapchat: https://bit.ly/3cC0V9d Discord: https://discord.gg/BaileySarian* RECOMMEND A STORY HERE: cases4bailey@gmail.com Business Related Emails: bailey@underscoretalent.com Business Related Mail: Bailey Sarian 4400 W. Riverside Dr., Ste 110-300 Burbank, CA 91505 ________ This podcast is Executive Produced by: Bailey Sarian & Kevin Grosch and Joey Scavuzzo from Made In Network Head Writer: Allyson Philobos Writer: Katie Burris Additional Writing: Jessica Charles Research provided by: Dr. Thomas Messersmith Special thank you to our Historical Consultant: Dr. Dustin Cranford Director: Brian Jaggers Additional Editing: Julien Perez and Maria Norris Post Supervisor: Kelly Hardin Production Management: Ross Woodruff Hair: Angel Gonzalez Makeup: Bailey Sarian ________ No matter what your summer brings: Tear. Pour. Live More. Go to https://www.liquidiv.com and get 20% off your first order with code DARKHISTORY at checkout. Personal styling for everyone—get started today at https://www.stitchfix.com/darkhistory. Start listening and discover what's beyond the edge of your seat. New members can try Audible now free for 30 days and dive into a world of new thrills. Visit https://www.audible.com/DARKHISTORY or text DARKHISTORY to 500-500. Start your initial free online visit today at https://www.forhers.com/DARKHISTORY. That's https://www.forhers.com/DARKHISTORY for your personalized hair loss treatment options. Individual Results may vary. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Price varies based on product and subscription plan. See website for full details, restrictions, and important safety information.
© 2020-2026 Ivy Podcast Discovery LLC
